Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial.

ABSTRACT:

Background

The effects of convalescent plasma (CP) therapy in hospitalised patients with coronavirus disease 2019 (COVID-19) remain uncertain. This study investigates the effect of CP on clinical improvement in these patients.

Methods

This is an investigator-initiated, randomised, parallel arm, open-label, superiority clinical trial. Patients were randomly (1:1) assigned to two infusions of CP plus standard of care (SOC) or SOC alone. The primary outcome was the proportion of patients with clinical improvement 28 days after enrolment.

Results

A total of 160 (80 in each arm) patients (66.3% critically ill, 33.7% severely ill) completed the trial. The median (interquartile range (IQR)) age was 60.5 (48-68) years; 58.1% were male and the median (IQR) time from symptom on

SUBMITTER: Sekine L 

PROVIDER: S-EPMC8287736 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature